Original article

Year : 2016  | Volume : 02 | Issue : 02  | Page : 23-28

The Role of High-sensitivity C-reactive Protein as a Cardiovascular Risk Marker in Essential Hypertension

S Vijayalakshmi1, K Pramila2, R Lalitha3

1Senior Assistant Professor, Department of Bio Chemistry, Government KAPV Medical College, Trichy

2Department of Bio Chemistry, Madras Medical College, Chennai

3Department of Bio Chemistry, Government Kilpauk Medical College, Chennai

Address for correspondence:

Dr. S Vijayalakshmi, 1893, Vasantha Colony, Anna Nagar, Chennai - 600 040, Tamil Nadu, India. Phone: +91-8056138065. E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Download Article


Background: Hypertension is a common and independent risk factor of cardiovascular disease, especially the coronary artery disease. The primary or essential hypertension can be classified further, based on the blood pressure measurements, done during initial assessment and diagnosis. The risk of complications does not correlate with the stage of hypertension as per the results of many studies done earlier. Hence, it is imperative to look for some way of assessing the risk of future cardiovascular complications in subjects (overt hypertensives as well as pre-hypertensives) to reduce the morbidity associated. The researchers all around the world are currently studying the role of various inflammatory markers as risk assessment tools in hypertension. High-sensitivity C-reactive protein (hs-CRP) is the most studied of all. This study is done with the aim to assess the cardiovascular risk in subjects diagnosed with essential hypertension, comparing their stage of hypertension and hs-CRP levels. Materials and Methods: A total of 150 subjects were selected in this study: 50 as controls, 50 as newly diagnosed/untreated patient group, and 50 as treated patient group. The hs-CRP was assayed using standard immunoturbidimetric assay and using a fully automated analyzer, and values compared statistically. There was a significant increase in the hs-CRP levels in the untreated patient group (3.93 ± 1.01) when compared to the control group (1.07 ± 0.39). Furthermore, the comparison between the hs-CRP levels in the untreated patient group versus treated patient group and showed a significant drop in levels of hs-CRP in the treated group (1.26 ± 0.54). Both of these above findings suggest that hs-CRP, which marks the level of subclinical inflammation, could be used to assess the risk of morbid events and also can be used as a tool to assess the response of patients to treatment offered. Conclusion: Thus, it is concluded that hs-CRP levels are significantly increased in untreated hypertensive subjects and the levels significantly drop the following treatment.

KEY WORDS:Blood pressure, cardiovascular, high-sensitivity C-reactive protein, hypertension, inflammation.

How to cite this article: Vijayalakshmi S, Pramila K, Lalitha. The role of high-sensitivity C-reactive protein as a cardiovascular risk marker in essential hypertension. J Med Sci Health 2016;2(2):23-28.


Globally, the prevalence of hypertension is rising.[1] At which point of measurement of blood pressure (BP), is the term hypertension used? Most data that are available during this present time indicate that there is no such sharp dividing point.[2] Actually, physicians are compelled to treat people who fall in the pre-hypertension levels of BP measurements.

Now, is there any guiding tool to help physicians begin the medical management for hypertension, other than the BP measurements alone? The usual risk factor evaluations do not always, accurately identify patients at risk of the atherothrombotic events. About half of all strokes and myocardial infarctions occur in patients with normal cholesterol levels as shown statistically. Hence, lipid profile may not be considered as risk assessment tool independently.

Inflammatory markers, such as interleukin-1 (IL-1) and IL-6, have less clinical utility because the assays, required for their assessment, are either inappropriate for routine clinical use or the protein of interest has too short a half-life for clinical evaluation.[3] The novel cardiac risk assessment tool, hs-CRP is gaining more recognition as a biomarker in essential hypertension to predict the degree of vascular pathology.[4] CRP is a pentraxin,[5] which means five berries (Greek word-Penta means five and Ragos mean Berries).

Inflammation after its onset leads to expression of pro-inflammatory cytokines, especially IL-1, which in turn expresses IL-6, which leads to increased expression of CRP gene, thereby the production of CRP is increased.[6] Many studies have said that CRP is not only a marker of inflammation in atherosclerosis but also an actual participant in the disease process. Actually, CRP binds to the phospholipid residues with high affinity and also with a large number of other autologous and extrinsic ligands. Thus, damaged endothelial membrane phospholipids also acts as ligands.

It also activates the complement, sustaining inflammation, and induces the monocytes to produce IL-6 that in turn induces C-reactive protein (CRP) production. Thus, CRP once formed can activate its own synthesis.[7]

It is shown that CRP enhances the expression of local endothelial cell surface adhesion molecules, monocyte chemotactic protein 1, endothelin 1, plasmalogen activator inhibitor-1 and reduces the endothelial nitric oxide (NO) bioactivity and also increases the tissue uptake of modified low-density lipoprotein.

Furthermore, studies say that the increased CRP levels are linked with a decrease in endotheliumdependent relaxation, and this endothelial dysfunction may progress, leading to vessel wall lesions and later on to atherosclerotic plaques.

In this way, CRP has proved to be having a causal role in the pathogenesis of hypertension and it is already a proved risk assessment tool for future stroke and coronary heart disease.[8]

The levels of hs-CRP indicate the risk, i.e., a level of < 1 mg/L is low risk, 1-3 mg/L is moderate risk, and > 3 mg/L is high risk.[9]

Materials and Methods

This study is a cross-sectional study among subjects attending the hypertension clinic, master health checkups, and Outpatient Department in Government Stanley Hospital. All study participants provided written, informed consent, and the study protocol was reviewed and approved by the institutional ethical committee review board.

Inclusion criteria
Those subjects who were healthy with average BP within normal limit were included as:

  • Control Group 1
  • Patients with new onset hypertension (untreated) were included as study Group 2
  • Patients, who were already taking regular treatment for hypertension, were included as study Group 3 (treated).


Exclusion criteria

  1. Smoking
  2. Alcoholism
  3. Chronic inflammatory conditions
  4. Tuberculosis
  5. Autoimmune diseases such as rheumatoid arthritis
  6. Diabetes mellitus
  7. Stroke
  8. Hepatic diseases
  9. Renal diseases
  10. Acute infections/sepsis
  11. Recent history of trauma
  12. Drug therapies such as lipid lowering agents and probenecid
  13. Gout
  14. Critically ill patients.
Study participants were included in this study following a detailed self-reported questionnaire and basic preliminary lab tests. The total number of subjects included in the study was 150. Out of this, 50 were new onset hypertensives (untreated patients), 50 were hypertensives on regular treatment (treated), and 50 were normotensive subjects (controls).
The sample size was calculated using the formula given below:[10]


Where, “n” is sample size, Z is constant, Zα is constant set according to the α error allowed, Z 1−β denotes constant set according to the power of the study, δ denotes the estimated standard deviation (SD), and Δ denotes the estimated effect size.

Our study was set with an allowed error of 0.05, confidence interval 95%, SD 1.01, effect size of 0.5, and so, the minimum sample size as per the formula given above comes around 50.[10]

After getting a written, informed consent from the selected subjects, a thorough general examination was done, and 2 BP recordings were taken ½ h apart. The average of the BP recordings was taken.

The sample from selected subjects was assayed for all the routine blood parameters such as glucose, urea, creatinine, liver function test, lipid profile using the usual kit methods using a fully automated analyzer.

Standard assays for CRP typically have a lower detection limit of 3-8 mg/L. Therefore, these assays lack the sensitivity within the lower-normal range and so cannot be used for atherosclerotic risk prediction. However, there are newer assay systems available in the market which are highly sensitive and can assay even lower levels of CRP. Many such “high-sensitivity (Hs)” or “ultra-sensitive” assays for CRP are now commercially available (“hs” in hs-CRP refers to “high sensitivity” assay).[11] Hs-CRP was also assayed by latex immunoturbidimetric assay (using diazyme assay kit) in the fully automated analyzer(Beckman Coulter AU 400 series).

Results and Statistics

The results, which were got in the present study, are given in the Tables 1-4 along with the relevant statistical correlation.

Table 2 shows that the mean age of the control group (Group 1) is 36.24 ± 5.157, untreated patients (Group 2) is 49.16 ± 7.046, and for the treated patients (Group 3) is 59.62 ± 7.540. The age between groups was tested using Chi-square test, and there is a significant difference between groups inferring age as an independent factor influencing the onset of hypertension.

About 92% of the control group (without any diseasenormotensives) are in ages 31-40, whereas only 16% of the untreated (newly diagnosed hypertensives) and 1% of the treated (known hypertensives on regular treatment) are between 31 and 40 years. Most of the untreated newly diagnosed hypertensives are between ages 51 and 60 years. In the case of the treated known hypertensives, the majority are between 51 and 70 years.

Thus, we can understand that the onset and diagnosis of hypertension are usually around 50 years, and the treatment for hypertension has to be continued once started.

It has been said in the literature that there are mild increases of hs-CRP in female subjects as compared to the males, and hence, Chi-square test was performed to compare the sex distribution among various groups. However, no significant difference is noted.

The mean hs-CRP of the control group was 1.0798 ± 0.39625, and it was significantly increased in untreated patients (mean is 3.9322 ± 1.01456).

It is known that the serum hs-CRP value < 1 mg/L signifies low risk, 1-3 mg/L intermediate risk, and > 3 mg/L high risk of developing atherosclerosis.

Hence, the untreated patients have a high risk for future atherothrombotic events as compared with the control.

Furthermore, the mean hs-CRP levels are low in treated patients as compared with the untreated group signifying the decrease in the inflammatory process following treatment.


The 7th report of the Joint National Committee on prevention, detection, evaluation, and treatment of high BP says that the people with systolic BP ≥120 mm Hg or diastolic BP ≥80 mm Hg are at increased risk of progressing to overt hypertension and need regular follow-ups. However, there is considerable variation in the rate of progression to overt hypertension. Physicians face the challenge of identifying people falling in this category of pre-hypertension who have a high risk of atherothrombotic events and are compelled to start intensive interventions even before the onset of overt hypertension with increase in BP readings.[12]

Of all the available markers, hs-CRP is the one most studied and also standard assays are available in the market at reasonable cost.

CRP, at concentrations known to predict adverse vascular events, by causing a decrease in activity of NO, in turn, inhibits vasodilatation, an important compensatory mechanism in chronic ischemia. Through this decrease in NO biosynthesis, it may lead to many diverse cardiovascular diseases. Risk reduction strategies designed to lower plasma CRP may be effective by improving NO bioavailability.[13]

Many large-scale cohort studies have shown that the levels of hs-CRP are an independent and strong predictor of future risk of myocardial infarction, stroke, peripheral arterial disease, and vascular death among individuals without known cardiovascular disease.[14-22]

In our present study, we have found that there is a significant association of increase levels of hs-CRP and hypertension and the degree of inflammation as attributed by the stage of hypertension and treatment history is also clearly associated with levels of hs-CRP.

Shafi Dar et al. have discussed the association between the BP and serum hs-CRP levels in their study conducted, in 2010, in a set of Kashmiri Indians. According to their study, individuals with pre-hypertension are more likely to have significantly increased levels of serum hs-CRP levels as compared to the normotensive control subjects, and they conclude that the difference in the elevation levels of hs-CRP was also found to be duration dependent. Patients with shorter duration of the hypertensive history of < 1 year had significantly elevated levels of hs-CRP as compared to patients with longer duration of hypertensive history (5 years).[23]

Similarly, Xu et al. have concluded that of a total of 767 hypertensives and 762 non-hypertensives people aged 30 or more who were selected as participants for their study and after the adjustments for the covariate factors, high level of CRP (≥2.54) was significantly associated with hypertension and the odds ratio being 1.337.[24]

With all the above-mentioned studies proving the causal link between hs-CRP and hypertension, there are still more recent studies, which prove the association of high hs-CRP levels in prehypertensive people leading to early onset of morbid cardiovascular events.

One such study was done by Sesso et al. which investigated 20,525 women aged 45 or above and followed up for average 7.8 years, and the results of their cohort study show that higher level of CRP was associated with one and half times increased risk of hypertension compared to lower level of CRP, which in turn says that there would be inflammatory pathologic process in development of hypertension and inflammatory reaction might be direct cause of hypertension.[25]

There are also several other studies done in the past few years having the same conclusions, showing a significant positive association of elevated hs-CRP levels, and the increased risk of future athero thrombotic events.[26,27]

Hommels et al. in their study have proved that that the hs-CRP levels were significantly raised in the 57 patients with confirmed atherosclerosis of the aorta (4.6 mg/L; P < 0.005) as compared to the 26 patients without any angiographic lesions (1.7 mg/L; P < 0.005). Moreover, in those with renal artery stenosis, levels of hs-CRP were more when the degree of stenosis was more than 50%.[26]

To conclude, serum hs-CRP levels are significantly elevated in newly diagnosed untreated hypertensive subjects as compared to the normotensive controls and treated hypertensives, putting them into a substantially increased risk of developing future atherothrombotic events, and hence, it is wise to begin treatment strategies in people with high hs-CRP levels even if their BP measurements is not markedly elevated.

Finally, the limitations of our study are:

  1. It is a cross-sectional study, and hence, the relationship between the study parameters and hypertension cannot be deemed causal in nature
  2. Residual confounding is of concern
  3. Single baseline measurement of the parameters was only done
  4. Subjects with diabetes mellitus were excluded, but those with latent diabetes were not ruled out.



  1. Park K. Park’s Text Book of Preventive and Social Medicine. 20th ed. Jabalpur: M/S Banarsidas Bhanot; 2009. p. 323.
  2. Genest J, Kuchel O. Text Book of Hypertension. In: Brehm JJ, Emery AEH, Rimoinn DL, et al., editors. 2nd ed. New York: McGraw-Hill Book Company; 1984. p. 3.
  3. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome and risk of incident cardiovascular events: An 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-97.
  4. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk predictions models for women. Ann Intern Med 2006;145:21-9.
  5. Wannamethee SG, Lowe GD, Whincup PH, Rumley A, Walker M, Lennon L. Physical activity and hemostatic and inflammatory variables in elderly men. Circulation 2002;105:1785-90.
  6. Bermudez EA, Rifai A, Buring J, Manson JE, Ridker PM. Inter relationship among circulating interleukin-6, C - reactive protein and traditional cardivascular risk factors in women. Arterioscler Thromb Vasc Biol 2002;22:1668-73.
  7. Pascin V. Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein mediated monocyte chemotactic attractant protein-1 induction in human endothelial cells by anti atherosclerosis drugs. Circulation 2001;103:2531-4.
  8. Ghosh TK, Ghosh S, Bhattacharjee D. C-reactive protein levels in women with pregnancy induced hypertension. Bangladesh J Med Sci 2011;10:213-8.
  9. Di Napoli M, Papa F. C-reactive proteins and cardiovascular risk indices in hypertensive Nigerians. Internet J Cardiovasc Res 2008;6:2.
  10. Kadam P, Bhalerao S. Sample size calculation. Int J Ayurveda Res 2010;1:55-7.
  11. Ridker PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103:1813-8.
  12. Wang TJ, Gona P, Larson MG, Levy D, Benjamin EJ, Tofler GH, et al. Multiple biomarkers and the risk of incident hypertension. Hypertension 2007;49:423-38.
  13. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
  14. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.
  15. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple risk factor intervention trial. Am J Epidemiol 1996;144:537-47.
  16. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
  17. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the cardiovascular health study and the rural health promotion project. Arterioscler Thromb Vasc Biol 1997;17:1121-27.
  18. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731-3.
  19. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
  20. Koenig W, Sund M, Froelich M, Fischer HG, Löwel H, Döring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation 1999;99:237-42.
  21. Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation, and the risk of coronary heart disease. Circulation 2000;101:252-7.
  22. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506-12. 23. Shafi Dar M, Pandith AA, Sameer AS, Sultan M, Yousuf A, Mudassar S. Hs-CRP: A potential marker for hypertension in Kashmiri population. Indian J Clin Biochem 2010;25:208-12.
  23. Xu T, Ju Z, Tong W, Hu W, Liu Y, Zhao L, et al. Relationship of C-reactive protein with hypertension and interactions between increased C-reactive protein and other risk factors on hypertension in Mongolian people, China. Circ J 2008;72:1324-8.
  24. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-51.
  25. Hommels MJ, van der Ven AJ, Kroon AA, Kessels AG, van Dieijen-Visser MP, van Engelshoven JA, et al. C-reactive protein, atherosclerosis and kidney function in hypertensive patients. J Hum Hypertens 2005;19:521-6.
  26. Folsom AR, Chambless LE, Ballantyne CM, Coresh J, Heiss G, Wu KK, et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: The atherosclerosis risk in communities study. Arch Intern Med 2006;166:1368-73.
Read 565 times Last modified on Tuesday, 21 June 2016 07:40

"Journal of Medical Sciences and Health” is a triannual, peer reviewed, open access, online and print journal of Adichunchanagiri Institute of medical Sciences"